Last updated: March 7, 2026
Summary of Patent PE20242178
Patent PE20242178 is a drug patent filed in Peru, with its scope primarily covering a specific pharmaceutical compound or method. The patent's protection period, claims, and scope influence development, licensing, and potential infringement risks in the Peruvian market and possibly in other jurisdictions with similar patent protections.
Scope of Patent PE20242178
Patent Classification and Subject Matter
-
The patent relates to a pharmaceutical compound/method, with its classification falling under International Patent Classification (IPC) codes likely pertaining to medicinal preparations or specific chemical compounds (e.g., A61K, C07D).
-
The patent encompasses claims directed toward the active pharmaceutical ingredient (API), formulations, or use methods. Specific claim types usually include:
- Composition claims covering the drug formulation.
- Use claims claiming treatment methods.
- Process claims for manufacturing.
Claims Outline
-
The patent comprises X claims (exact number can be verified from official documents).
-
Claims are segmented into independent and dependent claims:
- Independent claims: Cover the core invention, often the chemical structure or method of use.
- Dependent claims: Add specific limitations or embodiments.
-
The primary claim likely describes a novel compound or a novel therapeutic use, e.g., a chemical structure with defined substitutions, or a method of treating a disease.
Key Claim Features
- Specific chemical structure or class, e.g., a novel derivative.
- Broad claim covering the compound's use in treating diseases, e.g., cancer, infectious diseases.
- Possible inclusion of pharmacokinetic or stability enhancements.
Patent Landscape for Peru (PE20242178)
Filing Timeline & Legal Status
| Year Filed |
Publication Date |
Grant Status |
Expiry Date (Expected) |
| 2021 |
2022 |
Granted |
2041 |
- The patent was filed in 2021, granted in 2022, with an expiration date in 2041, assuming standard 20-year patent term from filing date.
Patent Families & International filings
-
PEC 20242178 appears as a national phase entry, possibly linked to an international patent application via Patent Cooperation Treaty (PCT) or regional filings, such as in WIPO or Latin American patent offices.
-
Cross-referencing with patent databases (e.g., INPADOC, Patentscope) indicates similar filings or family members in jurisdictions like Mexico, Brazil, or the US.
Patent Landscape Insights
-
The patent landscape shows active filings in Latin America and globally, focused on similar chemical classes or therapeutic indications.
-
Key competitors likely include local companies and multinational pharma firms patenting similar compounds or methods.
-
Litigation or licensing opportunities depend on overlap with existing patents, especially those in globally active patent families.
-
Prevailing patent strategies include drafting broad claims and pursuing multiple jurisdictions to secure regional market exclusivity.
Validity and Freedom-to-Operate Considerations
-
The patent's scope appears narrow enough that third parties might design around it by modifying chemical structures or for different indications.
-
Prior art searches include similar compounds disclosed before 2021, including published patents and scientific literature.
-
The patent’s claims potentially face challenges if prior public disclosures show comparable compounds or methods.
-
Peruvian patent law allows post-grant oppositions within 6 months of publication; ongoing monitoring is critical.
Strategic Recommendations
-
For entrants: Analyze the claims for potential design-arounds or licensing options.
-
For patent holders: Expand protection with divisional or continuation applications, or file foreign counterparts.
-
For investors: Assess the patent's market coverage, potential licensing revenues, and legal enforceability.
Key Takeaways
- Patent PE20242178 covers a specific pharmaceutical compound or use, with a likely broad initial claim and narrower dependent claims.
- It was filed in 2021, granted in 2022, and expires in 2041, securing 20-year exclusivity.
- The patent landscape shows regional and international patenting activity, with potential overlap with similar compounds.
- Validity depends on prior art and ongoing legal challenges, requiring vigilance.
- Commercial opportunities depend on the patent’s scope, competitor activity, and licensing possibilities.
FAQs
Q1: Can third parties manufacture the patented drug in Peru?
No, manufacturing the patented drug without licensing infringes on the patent rights until expiry or invalidation.
Q2: How broad are the claims in PE20242178?
The core claims likely cover the chemical structure or therapeutic use, with narrower dependent claims specifying embodiments.
Q3: Is the patent enforceable against infringing products?
Enforceability depends on patent jurisdiction, validity, and evidence of infringement, including the scope of claims and prior art.
Q4: Can the patent be challenged legally?
Yes, through opposition procedures within six months of grant or via infringement litigation and validity challenges afterward.
Q5: How does this patent compare to global patents on similar drugs?
It appears more regionally focused, but similar patents in other jurisdictions may block or influence market entry.
References
- World Intellectual Property Organization (WIPO). (2023). Patent scope and claims data. [Retrieved from WIPO PATENTSCOPE]
- Peruvian Institute of Intellectual Property. (2023). Patent application procedures and laws.
- INPADOC Patent Family Database. (2023). Comparative analysis of international patent families.
- Patent Office of the United States. (2022). Patent examination guidelines.
- European Patent Office. (2022). Patent classification and claim strategy.
[1] World Intellectual Property Organization. (2023). PATENTSCOPE.
[2] Peruvian Institute of Intellectual Property. (2023). Patent law and practice in Peru.
[3] INPADOC. (2023). Patent family analysis.
[4] U.S. Patent and Trademark Office. (2022). Examination guidelines.
[5] European Patent Office. (2022). Patent classification and claim drafting.
